BPC-157 + TB-500 Blend

This guide covers our pre-blended vial — 5 mg BPC-157 and 5 mg TB-500 combined — the form the two peptides are most commonly researched together in. BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid chain — derived from a partial sequence of a naturally-occurring protein in human gastric juice, continuously researched since 1991, primarily out of the University of Zagreb. TB-500 is a synthetic fragment corresponding to an active region of thymosin beta-4, a naturally-occurring 43-amino-acid protein studied mainly in animal-model recovery research. Both compounds carry a substantial animal-model literature and a small but growing human trial base.

Watch

▶ Dr Admits - I Was WRONG About The Wolverine Stack

Mechanism

BPC-157's research literature centers on three overlapping mechanisms:

• Angiogenesis — promotion of new blood-vessel formation at the injury site, which speeds nutrient delivery to healing tissue.
• Fibroblast activity — upregulation of the cells responsible for producing collagen and extracellular matrix.
• Nitric oxide pathway modulation — interaction with the eNOS system, relevant to both vascular and gastrointestinal healing.

These mechanisms combine to explain the peptide's broad footprint across injury models — tendon, ligament, muscle, gut lining, cornea, and burn wound.

TB-500's mechanism

• Actin binding. TB-500 retains the actin-binding site of its parent protein, thymosin beta-4, relevant to cytoskeletal remodeling during cell migration.
• Cell migration. Studied for its role in mobilizing progenitor cells to sites of tissue injury.
• Angiogenesis. A parallel literature to BPC-157 on new blood-vessel formation at injury sites — one reason the two are frequently studied together.

Common research protocols

This blend is one of the few in this category where community research literature consistently describes two distinct aggression levels rather than one fixed protocol. Dosing figures below reflect that literature — not medical advice.

• Reconstitution: the 10 mg combined vial (5 mg BPC-157 + 5 mg TB-500) with 2 mL bacteriostatic water yields 5 mg/mL total (2.5 mg/mL of each peptide, or 25 mcg per U-100 unit for each).
• Draw: 10 units on a U-100 insulin syringe for a 250 mcg dose of each peptide (0.10 mL); scale units up proportionally for the advanced tier.
• Cycle: most protocols cycle 4-8 weeks on / 2-4 weeks off; long uninterrupted use has not been well-studied.

Why they're stacked

BPC-157 and TB-500 are frequently paired in the recovery literature and typically dosed together over 4 to 6 weeks — this is the most common way either compound is actually researched in combination, which is why we stock them as a pre-blended vial rather than only individually.

What the human data shows — and doesn't

Animal models (extensive). BPC-157 has been studied across gastric ulcer, Achilles tendon-to-bone reattachment, transected muscle, colitis, burn wound, and corneal healing models, with consistent findings: accelerated tissue recovery, increased angiogenesis at the injury site, reduced inflammatory infiltrate. TB-500 has separately been studied in cardiac, dermal, and skeletal-muscle injury models.

Human data (growing but limited). A handful of small-scale observational studies and a growing anecdotal record for both compounds. No completed Phase 3 human trial for the general recovery indication for either, as of publication.

What we do not know. Long-term human safety data (studies rarely exceed 12 weeks) for either peptide; interaction profile with common medications; pharmacokinetics of oral versus subcutaneous administration in humans; and how the two compounds interact pharmacokinetically when dosed together, specifically.

Side-effect profile in the literature

Reported adverse effects in animal-model and small human observational studies have been mild and infrequent for both peptides — typically injection-site discomfort, occasional mild flushing or fatigue on the first dose. No consistent signal for serious adverse events has been reported at commonly-studied doses.

This is not a safety guarantee. Long-term human safety data does not yet exist at scale for either compound. Buyers researching human application should coordinate with a licensed clinician.

Reconstitution & handling

The blend ships as a single lyophilized 10 mg vial (5 mg BPC-157 + 5 mg TB-500). Reconstitute with 2 mL bacteriostatic water for a combined 5 mg/mL concentration (2.5 mg/mL of each peptide); refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How We Work page.

Primary literature (selected)

Primary literature reviewed for this guide. Full list, including TB-500-specific sources, available on request via contact. See also the dedicated TB-500 deep-dive for citations specific to that peptide.